SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 8, 2004
Date of Report
(Date of earliest event reported)
RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
000-30959 |
94-3199149 |
|
(Commission File Number) |
(I.R.S. Employer Identification No.) |
967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)
(650) 314-3400
(Registrant's telephone number, including area code)
Item 5. Other Events and Required FD Disclosure.
On June 8, 2004, RITA Medical Systems, Inc., a Delaware corporation, announced that early results from an international multicenter prospective clinical trial show a 92% survival rate in stage 1 non-small cell lung cancer patients treated with radiofrequency ablation as the sole anti-cancer treatment. A copy of the release is attached as Exhibit 99.1 hereto and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
| |
RITA Medical Systems, Inc. |
|
|
|
| Date: June 9 2004 |
By: |
/s/ Donald Stewart |
| |
Donald Stewart, Chief Financial Officer and
Vice President Finance and Administration |
RITA MEDICAL SYSTEMS, INC.
INDEX TO EXHIBITS
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release of RITA Medical Systems, Inc. dated June 8, 2004. |
|